ABSTRACT
There is no consensus approach to safety screening for immune intervention in clinical neuroimmunology. An immunosuppression risk evaluation checklist was used as an audit tool to assess real-world immunosuppression risk management and formulate recommendations for quality improvements in patient safety. Ninety-nine patients from two centres with 27 non-MS diagnoses were included. An average of 1.9 comorbidities with the potential to adversely impact morbidity and mortality associated with immunosuppression were identified. Diabetes and smoking were the most common, however a range of rarer but potentially life-threatening co-morbid disorders in the context of immunosuppression were identified. Inadequate documentation of risk mitigation tasks was common at 40.1% of total tasks across both cohorts. A routine, systematic immunosuppression checklist approach should be considered to improve immunosuppression risk management in clinical neuroimmunology practice.
Subject(s)
Checklist , Clinical Audit , Immune System Diseases/epidemiology , Immune System Diseases/physiopathology , Immunosuppression Therapy , Australia , Clinical Audit/methods , Clinical Audit/standards , Cohort Studies , Cross-Sectional Studies , Female , Humans , Immune System Diseases/mortality , Male , Risk Management , United KingdomABSTRACT
A case of acute limb ischemia secondary to iliac artery dissection is presented along with its management. Images highlighting the features of dissection on a noncontrast computed tomography (CT) scan are presented and discussed.
